Short running head: IPF baseline outcome prediction Word count: 4310 wordsThis article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org At a Glance: Quantification of CT parenchymal patterns in idiopathic pulmonary fibrosis using computer tools has been suggested as a method that can improve on mortality prediction using visual CT scoring. As computer technology advances, it has now become possible to study CT parenchymal features that have no visual correlate. Our study demonstrates that computer-derived vessel-related structure scores can outperform current gold-standard measures of outcome in idiopathic pulmonary fibrosis such as forced vital capacity decline. Specifically, we demonstrate that using thresholds of computer-derived vessel-related structure scores for cohort enrichment can identify idiopathic pulmonary fibrosis patients that respond to antifibrotic medication with reduced FVC decline and improved survival.Importantly, the vessel-related structure thresholds would be able to reduce idiopathic pulmonary fibrosis drug-trial population sizes by 26% thereby dramatically reducing study costs. JJ and AUW were also involved in the conception and design of the study.BJB, RK and SR invented and developed CALIPER. They were involved in processing the raw CT scans and in generation of figures but were not involved with the analysis or interpretation of the data in the study. When used as a cohort enrichment tool, a CALIPER VRS score >4.4% of the lung was able to reduce the requisite sample size of an IPF drug trial by 26%.
Conclusions:Our study has validated a new quantitative CT measure in IPF patients fulfilling drug trial entry criteria, the VRS scores, that outperformed current goldstandard measures of outcome. When used for cohort enrichment in an IPF drugtrial setting, VRS threshold scores can reduce a required IPF drug trial population size by 25%, thereby limiting prohibitive trial costs. Importantly VRS scores identify patients in whom antifibrotic medication prolongs life and reduces forced vital capacity decline.
6